Coronavirus Disease 2019 Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection in the United States Before the Delta- and Omicron-Associated Surges: A Retrospective Cohort Study of Repeat Blood Donors.

The Journal of Infectious Diseases Pub Date : 2022-11-01 DOI:10.1093/infdis/jiac318

Eduard Grebe, Elaine A Yu, Marjorie D Bravo, Alex Welte, Roberta L Bruhn, Mars Stone, Valerie Green, Phillip C Williamson, Leora R Feldstein, Jefferson M Jones, Michael P Busch, Brian Custer

{"title":"Coronavirus Disease 2019 Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection in the United States Before the Delta- and Omicron-Associated Surges: A Retrospective Cohort Study of Repeat Blood Donors.","authors":"Eduard Grebe, Elaine A Yu, Marjorie D Bravo, Alex Welte, Roberta L Bruhn, Mars Stone, Valerie Green, Phillip C Williamson, Leora R Feldstein, Jefferson M Jones, Michael P Busch, Brian Custer","doi":"10.1093/infdis/jiac318","DOIUrl":null,"url":null,"abstract":"Background: To inform public health policy, it is critical to monitor coronavirus disease 2019 vaccine effectiveness (VE), including against acquiring infection.Methods: We estimated VE using self-reported vaccination in a retrospective cohort of repeat blood donors who donated during the first half of 2021, and we demonstrated a viable approach for monitoring VE via serological surveillance.Results: Using Poisson regression, we estimated an overall VE of 88.8% (95% confidence interval, 86.2-91.1), adjusted for demographic covariates and variable baseline risk.Conclusions: The time since first reporting vaccination, age, race and/or ethnicity, region, and calendar time were statistically significant predictors of incident infection.","PeriodicalId":509652,"journal":{"name":"The Journal of Infectious Diseases","volume":" ","pages":"1556-1561"},"PeriodicalIF":0.0000,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9384661/pdf/jiac318.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/infdis/jiac318","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background: To inform public health policy, it is critical to monitor coronavirus disease 2019 vaccine effectiveness (VE), including against acquiring infection.

Methods: We estimated VE using self-reported vaccination in a retrospective cohort of repeat blood donors who donated during the first half of 2021, and we demonstrated a viable approach for monitoring VE via serological surveillance.

Results: Using Poisson regression, we estimated an overall VE of 88.8% (95% confidence interval, 86.2-91.1), adjusted for demographic covariates and variable baseline risk.

Conclusions: The time since first reporting vaccination, age, race and/or ethnicity, region, and calendar time were statistically significant predictors of incident infection.

查看原文本刊更多论文

在Delta和omicron相关激增之前，美国2019年冠状病毒病疫苗对严重急性呼吸综合征冠状病毒感染的有效性:一项对重复献血者的回顾性队列研究。

背景:为了为公共卫生政策提供信息，监测2019冠状病毒病疫苗的有效性(VE)至关重要，包括防止获得感染。方法:我们在2021年上半年献血的重复献血者的回顾性队列中使用自我报告的疫苗接种来估计VE，并展示了一种通过血清学监测来监测VE的可行方法。结果:使用泊松回归，我们估计总体VE为88.8%(95%置信区间，86.2-91.1)，调整了人口统计学协变量和可变基线风险。结论:首次报告接种疫苗的时间、年龄、种族和/或民族、地区和日历时间是感染事件的统计显著预测因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

The Journal of Infectious Diseases

自引率

0.00%

发文量